Literature DB >> 33342297

Tracheostomy in Patients on Venovenous Extracorporeal Membrane Oxygenation: Is It Safe?

Katherine M Kelley1,2, Samuel M Galvagno1,2, Marianne Wallis2, Michael A Mazzeffi2, Kristopher Deatrick2, Richard Betzold1,2, Thomas Scalea1,2, Jay Menaker1,2.   

Abstract

BACKGROUND: The anticoagulation and coagulopathy associated with venovenous extracorporeal membrane oxygenation (VV-ECMO) lead to concern for increased risks of tracheostomy. The purpose of this study is to evaluate the safety of tracheostomy in patients on VV-ECMO.
METHODS: Patients admitted between November 2015 and January 2019 to a dedicated intensive care unit for VV-ECMO were reviewed retrospectively.
RESULTS: 96 patients underwent tracheostomy. Tracheostomy was performed percutaneously in 51 patients, open in 24, and hybrid in 21. 28 patients had postprocedure bleeding which was from the tracheostomy site in 13, the airway in 13, and both in 2. 6 patients had major tracheostomy site bleeding and 3 patients had major airway bleeding. 7 patients had minor tracheostomy site bleeding, 10 patients had minor airway bleeding, and 2 patients had minor bleeding at both. Bleeding complications were more common following percutaneous tracheostomy. Being on anticoagulation prior to tracheostomy was protective. DISCUSSION: Bleeding following tracheostomy in VV-ECMO is common with higher bleeding rates observed for those done percutaneously. Most complications were minor. Tracheostomy in patients on VV-ECMO appears safe.

Entities:  

Year:  2020        PMID: 33342297     DOI: 10.1177/0003134820979595

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  1 in total

1.  Tracheostomy Practices and Outcomes in Patients With COVID-19 Supported by Extracorporeal Membrane Oxygenation: An Analysis of the Extracorporeal Life Support Organization Registry.

Authors:  Joseph G Kohne; Graeme MacLaren; Leigh Cagino; Philip S Boonstra; Daniel Brodie; Ryan P Barbaro
Journal:  Crit Care Med       Date:  2022-05-16       Impact factor: 9.296

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.